JP2017137289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017137289A5 JP2017137289A5 JP2016152940A JP2016152940A JP2017137289A5 JP 2017137289 A5 JP2017137289 A5 JP 2017137289A5 JP 2016152940 A JP2016152940 A JP 2016152940A JP 2016152940 A JP2016152940 A JP 2016152940A JP 2017137289 A5 JP2017137289 A5 JP 2017137289A5
- Authority
- JP
- Japan
- Prior art keywords
- risk
- cystic fibrosis
- medicament
- patient
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 66
- 201000003883 Cystic fibrosis Diseases 0.000 claims 62
- 230000002685 pulmonary effect Effects 0.000 claims 28
- 229940079593 drug Drugs 0.000 claims 26
- 239000000443 aerosol Substances 0.000 claims 21
- 239000003795 chemical substances by application Substances 0.000 claims 21
- 230000005713 exacerbation Effects 0.000 claims 20
- 210000004072 lung Anatomy 0.000 claims 17
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 16
- 150000001768 cations Chemical class 0.000 claims 15
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 13
- 208000032376 Lung infection Diseases 0.000 claims 13
- 229960003376 levofloxacin Drugs 0.000 claims 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 10
- 208000035143 Bacterial infection Diseases 0.000 claims 9
- 239000003242 anti bacterial agent Substances 0.000 claims 9
- 208000022362 bacterial infectious disease Diseases 0.000 claims 9
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 8
- 230000003115 biocidal effect Effects 0.000 claims 8
- 229910052749 magnesium Inorganic materials 0.000 claims 8
- 239000011777 magnesium Substances 0.000 claims 8
- 229960001699 ofloxacin Drugs 0.000 claims 8
- 229940124307 fluoroquinolone Drugs 0.000 claims 7
- 210000003296 saliva Anatomy 0.000 claims 7
- 229940088710 antibiotic agent Drugs 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 229910052742 iron Inorganic materials 0.000 claims 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 4
- 229910052791 calcium Inorganic materials 0.000 claims 4
- 239000011575 calcium Substances 0.000 claims 4
- 229910052802 copper Inorganic materials 0.000 claims 4
- 239000010949 copper Substances 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000011701 zinc Substances 0.000 claims 4
- 229910052725 zinc Inorganic materials 0.000 claims 4
- 206010063659 Aversion Diseases 0.000 claims 3
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims 3
- 229960003644 aztreonam Drugs 0.000 claims 3
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 230000012953 feeding on blood of other organism Effects 0.000 claims 2
- 229960000707 tobramycin Drugs 0.000 claims 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 2
- KPPBAEVZLDHCOK-JHBYREIPSA-N (2s,3s)-3-[[(2z)-2-(2-azaniumyl-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonate;(2s)-2,6-diaminohexanoic acid Chemical group NCCCC[C@H](N)C(O)=O.O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 KPPBAEVZLDHCOK-JHBYREIPSA-N 0.000 claims 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010024264 Lethargy Diseases 0.000 claims 1
- 108010040201 Polymyxins Proteins 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 206010040744 Sinus headache Diseases 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 230000004596 appetite loss Effects 0.000 claims 1
- 229950010471 aztreonam lysine Drugs 0.000 claims 1
- 230000036760 body temperature Effects 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 229960002549 enoxacin Drugs 0.000 claims 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229960003923 gatifloxacin Drugs 0.000 claims 1
- 229960003170 gemifloxacin Drugs 0.000 claims 1
- ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 claims 1
- 229960002422 lomefloxacin Drugs 0.000 claims 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 claims 1
- 235000021266 loss of appetite Nutrition 0.000 claims 1
- 208000019017 loss of appetite Diseases 0.000 claims 1
- 230000004199 lung function Effects 0.000 claims 1
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 1
- 229960003702 moxifloxacin Drugs 0.000 claims 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims 1
- 229960001180 norfloxacin Drugs 0.000 claims 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims 1
- 229960004236 pefloxacin Drugs 0.000 claims 1
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 claims 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004954 sparfloxacin Drugs 0.000 claims 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021173092A JP2022028674A (ja) | 2016-02-05 | 2021-10-22 | 嚢胞性線維症のためのフルオロキノロン製剤 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662292065P | 2016-02-05 | 2016-02-05 | |
| US62/292,065 | 2016-02-05 | ||
| US201662293554P | 2016-02-10 | 2016-02-10 | |
| US62/293,554 | 2016-02-10 | ||
| US201662348439P | 2016-06-10 | 2016-06-10 | |
| US62/348,439 | 2016-06-10 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021173092A Division JP2022028674A (ja) | 2016-02-05 | 2021-10-22 | 嚢胞性線維症のためのフルオロキノロン製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017137289A JP2017137289A (ja) | 2017-08-10 |
| JP2017137289A5 true JP2017137289A5 (enExample) | 2019-10-03 |
| JP6966835B2 JP6966835B2 (ja) | 2021-11-17 |
Family
ID=59500283
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016152940A Active JP6966835B2 (ja) | 2016-02-05 | 2016-08-03 | 嚢胞性線維症のためのフルオロキノロン製剤 |
| JP2021173092A Pending JP2022028674A (ja) | 2016-02-05 | 2021-10-22 | 嚢胞性線維症のためのフルオロキノロン製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021173092A Pending JP2022028674A (ja) | 2016-02-05 | 2021-10-22 | 嚢胞性線維症のためのフルオロキノロン製剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210113579A1 (enExample) |
| EP (1) | EP3411503A4 (enExample) |
| JP (2) | JP6966835B2 (enExample) |
| MA (1) | MA43981A (enExample) |
| WO (1) | WO2017136516A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102325532B (zh) | 2008-10-07 | 2015-06-17 | Mpex医药有限公司 | 用于减轻肺部炎症的左氧氟沙星吸入剂 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8080394B2 (en) * | 2007-04-27 | 2011-12-20 | Brigham And Women's Hospital | Method for determining predisposition to pulmonary infection |
| CN102325532B (zh) * | 2008-10-07 | 2015-06-17 | Mpex医药有限公司 | 用于减轻肺部炎症的左氧氟沙星吸入剂 |
| KR20120034626A (ko) * | 2009-04-24 | 2012-04-12 | 엠펙스 파마슈티컬즈, 인코포레이티드 | 플루오로-퀴놀론을 사용하여 폐의 세균성 감염을 치료하는 방법 |
| LT2473170T (lt) * | 2009-09-04 | 2019-10-10 | Horizon Orphan Llc | Aerozolizuoto levofloksacino panaudojimas cistinės fibrozės gydymui |
-
2016
- 2016-08-03 JP JP2016152940A patent/JP6966835B2/ja active Active
-
2017
- 2017-02-02 US US16/971,945 patent/US20210113579A1/en not_active Abandoned
- 2017-02-02 EP EP17748127.2A patent/EP3411503A4/en not_active Withdrawn
- 2017-02-02 MA MA043981A patent/MA43981A/fr unknown
- 2017-02-02 WO PCT/US2017/016161 patent/WO2017136516A1/en not_active Ceased
-
2021
- 2021-10-22 JP JP2021173092A patent/JP2022028674A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ719761A (en) | Aerosol fluoroquinolone formulations for improved pharmacokinetics | |
| KR100824075B1 (ko) | 일반 감기, 알레르기성 비염 및 호흡기에 관련된 감염 증상의 치료 방법 | |
| CA2773033C (en) | Use of aerosolized levofloxacin for treating cystic fibrosis | |
| JP2018513188A5 (enExample) | ||
| CN102711760A (zh) | 雾化抗生素用于治疗慢性阻塞性肺病的用途 | |
| KR20190009294A (ko) | 비강 울혈을 치료/예방하기 위한 카르복실산 | |
| JP6077725B1 (ja) | 呼吸器感染症治療剤 | |
| Mori et al. | Management of acute rhinosinusitis | |
| JP2022028674A (ja) | 嚢胞性線維症のためのフルオロキノロン製剤 | |
| Tran et al. | Burn sepsis in children | |
| TWI818910B (zh) | 吸入性肺炎、肺化膿症或肺膿瘍之治療劑 | |
| Chacko et al. | Is it the end of the road for inhaled antibiotic therapy in ventilator-associated pneumonia? | |
| HK40098387A (en) | Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess | |
| HK40067557B (en) | Respiratory infection treating agent | |
| Amini et al. | A comparing study of clarithromycin XL with co-amoxiclav for treatment of chronic sinusitis; a clinical trial | |
| CN121197162A (zh) | 吸入性肺炎、肺化脓或肺脓肿的治疗剂 | |
| MX2025002408A (es) | Composicion farmaceutica en polvo seco y metodos para tratar infecciones del tracto respiratorio | |
| AU2015275224C1 (en) | Use of aerosolized levofloxacin for treating cystic fibrosis | |
| CN102198133B (zh) | 一种8-二氟甲氧基氟喹诺酮及其组合物在治疗结核病中的应用 | |
| Wadhwa et al. | Therapeutic efficacy of enrofloxacin (Quinlntas) in neonatal calf pneumonia. | |
| JP2022536932A5 (enExample) | ||
| NZ758839A (en) | Glycopeptide derivative compounds and uses thereof | |
| Schifter | Cancer and pallative care: Oral and dental manifestations, considerations and complications | |
| Braun et al. | Ciprofloxacin in respiratory tract infections: a phase IV surveillance study | |
| NZ758839B2 (en) | Glycopeptide derivative compounds and uses thereof |